Industry Briefs

Premium

MDS Q1 Revs Down 13 Percent, Mass Spec Unit Down 27 Percent; Renews Shareholders Rights Plan

MDS reported last week that its first-quarter revenues fell 13 percent year over year, with its MDS Analytical Technologies segment, which houses its mass spectrometry business, posting a 27 percent decline in revenues.

The firm brought in total revenues of $257 million for the three-month period ended Jan. 31. It said that excluding the impact of foreign exchange, acquisitions, and divestitures, revenues were down 1 percent compared to the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.